A role for bone turnover markers β-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346:564–569.
   PubMed Web of Science ®Google Scholar
• Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone. 2008;42:1007–1013.
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. JCO. 1989;7:1909–1914.
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483–2494.
   PubMed Web of Science ®Google Scholar
• Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood. 1997;90:3743–3750.
   PubMed Web of Science ®Google Scholar
• Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69: 37–42.
   PubMed Web of Science ®Google Scholar
• Ting KR, Brady JJ, Hameed A, et al. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016;173:82–88.
   PubMed Web of Science ®Google Scholar
• Abildgaard N, Brixen K, Kristensen JE, et al. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol. 2003;120:235–242.
   PubMed Web of Science ®Google Scholar
• Terpos E. Biochemical markers of bone metabolism in multiple myeloma. Cancer Treat Rev. 2006;32(Suppl 1): 15–19.
   PubMed Web of Science ®Google Scholar
• Woitge HW, Horn E, Keck AV, et al. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem. 2001;47:686–693.
   PubMed Web of Science ®Google Scholar
• Corso A, Arcaini L, Mangiacavalli S, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica. 2001;86:394–398.
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Suquia B, Queizan JA, et al. Bone remodelation markers are useful in the management of monoclonal gammopathies. Hematol J. 2004;5: 480–488.
   PubMedGoogle Scholar
• Szulc P, Bauer DC, Eastell R. Biochemical markers of bone turnover in osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames (IA), USA: John Wiley & Sons, Inc.; 2013. p. 297–306.
   Google Scholar
• Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem. 2008;54:188–196.
   PubMed Web of Science ®Google Scholar
• Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med. 2012;32:105–112.
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010;24:1700–1712.
   PubMed Web of Science ®Google Scholar
• Salmon S, Cassady J. Plasma cell neoplasms. In: De Vita VT, Hellman S, Rosenberg SA, editor. Cancer: principles and practice in oncology. 4th ed. Vol. 2. Philadelphia (PA): Lippincott; 1993. p. 1984–2025.
   Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854.
   PubMed Web of Science ®Google Scholar
• Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem. 2001;47:1410–1414.
   PubMed Web of Science ®Google Scholar
• Djunic I, Elezovic I, Marinkovic M, et al. Osteolytic lesions marker in multiple myeloma. Med Oncol. 2011;28:237–240.
   PubMed Web of Science ®Google Scholar
• Mathiot C, Mary JY, Tartour E, et al. Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 1996;95:660–665.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. JCO. 2005;23:5668–5674.
   PubMed Web of Science ®Google Scholar
• Laroche M, Attal M, Dromer C. Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol. 1996;15:347–352.
   PubMed Web of Science ®Google Scholar
• Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2004;126:686–689.
   PubMed Web of Science ®Google Scholar
• Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119:1728–1731.
   PubMed Web of Science ®Google Scholar
• Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002; 30:886–890.
   PubMed Web of Science ®Google Scholar
• Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017;28:2541–2556.
   PubMed Web of Science ®Google Scholar
• Dizdar O, Barista I, Kalyoncu U, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol. 2007;82:185–191.
   PubMed Web of Science ®Google Scholar
• Samani KK, Brazier M, Mathiot C, et al. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Ann Hematol. 2005; 84:19–24.
   PubMed Web of Science ®Google Scholar
• Scudla V, Pika T, Budikova M, et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma. 2010;57:102–110.
   PubMed Web of Science ®Google Scholar
• Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA. 2010;107:5124–5129.
   PubMed Web of Science ®Google Scholar
• Kassen D, Lath D, Lach A, et al. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. Br J Haematol. 2016;172:64–79.
   PubMed Web of Science ®Google Scholar
• Vallet S, Bashari MH, Fan FJ, et al. Pre-osteoblasts stimulate migration of breast cancer cells via the HGF/MET pathway. PLoS One. 2016;11:e0150507.
   PubMed Web of Science ®Google Scholar
• Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer. 2016;16:373–386.
   PubMed Web of Science ®Google Scholar
• Thurairaja R, Iles RK, Jefferson K, et al. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int. 2006;76:67–71.
   PubMed Web of Science ®Google Scholar
• Klepzig M, Jonas D, Oremek GM. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res. 2009;29:671–673.
   PubMed Web of Science ®Google Scholar
• Klepzig M, Sauer-Eppel H, Jonas D, et al. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. Anticancer Res. 2008; 28:2443–2446.
   PubMed Web of Science ®Google Scholar
• Lumachi F, Santeufemia DA, Del Conte A, et al. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res. 2013;33:2593–2596.
   PubMed Web of Science ®Google Scholar
• Pollmann D, Siepmann S, Geppert R, et al. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res. 2007;27:1853–1862.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dagan A, Robenshtok E, et al. Bone mineral density utilization in patients with newly diagnosed multiple myeloma. Hematol Oncol. 2017;35:703–710.
   PubMed Web of Science ®Google Scholar